Spanish 
English 
Respiratory Syncytial Virus and Incidence of Cardiovascular Events: A Nationwide Self-Controlled Case Series Analysis
This study was conducted by using the nationwide Danish health care registries, which provide individual-level data on demographic characteristics, medical diagnoses, prescription claims, and microbiology test results with complete data linkage for all citizens. identified all citizens aged ≥65 years who tested positive for RSV from September 16, 2022, through May 2023. They found that the incidence of both HF hospitalization and ischemic stroke were four to eight times higher during the 14 days after testing positive for RSV compared with the control period and the incidence was elevated by a factor of 6 compared with the control period.
Comorbidities Associated with Different Degrees of Severity in Children and Young People Hospitalized with Acute COVID-19
This is a prospective cohort study with 2,326 hospitalized children and young people with coronavirus disease 2019 in Spain and Colombia, 36.4% had comorbidities. Asthma, recurrent wheezing, chronic neurological, cardiac and pulmonary diseases significantly increased the risk of severe outcomes such as death, mechanical ventilation and intensive care unit admission. They conclude: The incremental risk with additional comorbidities underscores the importance of targeted vaccination strategies for vulnerable children and young people populations.
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
A total of 219 healthcare workers received Novavax, and 369 received the Pfizer product. Two and seven days after immunization, they completed a questionnaire on reactogenicity symptoms and their effects on daily activities. Participants included physicians (20.4% of the total), nurses (19.2%), and medical assistants (11.9%). The preliminary results were presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025 in Vienna. On average, workers who received Novavax had 1.7 systemic symptoms, compared with 2.8 in Pfizer recipients. In total, 43.8% of Pfizer vaccinees reported at least one symptom of moderate or higher grade, compared with 24.2% of Novavax recipients. Workers who received Novavax reported 12.5% fewer local reactions than those who received the Pfizer vaccine. Average hours of side effect–related reduced activity were lower in Novavax recipients than in Pfizer vaccinees (0.7 vs 1.4 hours of missed work and 0.8 vs 2.4 hours of lower productivity).
Kidney Function Following COVID-19 in Children and Adolescent
Results are from a robust retrospective cohort study used data from 19 health institutions in the National Institutes of Health Researching COVID to Enhance Recovery (RECOVER) initiative from March 1, 2020, to May 1, 2023. Among 1,900,146 pediatric patients (487 378 with and 1 412 768 without COVID-19), 969 937 (51.0%) were male, the mean (SD) age was 8.2 (6.2) years, and a range of comorbidities was represented. SARS-CoV-2 infection was associated with higher risk of new-onset chronic kidney disease (CKD) stage 2 or higher (HR, 1.17; 95% CI, 1.12-1.22) and CKD stage 3 or higher (HR, 1.35; 95% CI, 1.13-1.62). In those with pre-existing CKD, COVID-19 was associated with an increased risk of composite kidney events (HR, 1.15; 95% CI, 1.04-1.27) at 28 to 179 days. Children with acute-phase AKI had elevated HRs (1.29; 95% CI, 1.21-1.38) at 90 to 179 days for composite outcomes. They observed an increased risk of a composite outcome of at least 50% eGFR decline, eGFR of 15 mL/min/1.73 m2 or less, dialysis, kidney transplant, or ESKD diagnosis. These findings align with prior research indicating that COVID-19 infection elevates the risk of kidney outcomes.
Cardiovascular Post-acute Sequelae of SARS-CoV-2 in Children and Adolescents: Cohort Study Using Electronic Health Records
This paper assessed the risk of a number of cardiac signs, symptoms, and conditions 28-179 days after SARS-CoV-2 infection using electronic health records (EHR) data from 19 children’s hospitals and health institutions from the United States within the RECOVER consortium between March 2020 and September 2023. The cohort included 297,920 SARS-CoV-2-positive individuals and 915,402 SARS-CoV-2-negative controls. Every individual had at least a six-month follow-up after cohort entry. They found that children and adolescents with prior SARS-CoV-2 infection are at a significant increased risk of various cardiovascular outcomes, including hypertension, ventricular arrhythmias, myocarditis, heart failure, cardiomyopathy, cardiac arrest, thromboembolism, chest pain, and palpitations, compared to uninfected controls.
Situation Dashboards
World Health Organization (WHO)
Johns Hopkins University (JHU)
COVID-19 in US and Canada
